TY - JOUR AU - Yomayusa González, Nancy AU - Low Padilla, Eduardo AU - de la Hoz Siegler, Ilich AU - Chacón, Kelly AU - Acevedo Peña, Juan AU - Barrero Garzón, Liliana AU - Barrera Barinas, Alexander AU - Tolosa Pérez, Natalia AU - Castillo Niuman, Andrea AU - Guevara Pulido, Fredy AU - Castelblanco Cuevas, Diana AU - Pinzón Flórez, Carlos AU - Mendivelso Duarte, Fredy AU - Cantor Cruz, Francy AU - Castillo Gutiérrez, Ana AU - Gómez Gómez, Olga AU - Ávila, Adriana AU - Guevara, Claudia AU - Álvarez Moreno, Carlos AU - Rojas Gambasica, José AU - Arbeláez Duque, Carlos Miguel AU - García Guarín, Bibiana AU - Cárdenas Rodríguez, Martha AU - Robayo Rodríguez, Sandra AU - Torres Castro, Marcela PY - 2020/04/14 Y2 - 2024/03/28 TI - Use of evidence summaries to inform pharmacological treatment of people with suspected or diagnosed SARS-CoV-2 / COVID-19 respiratory infection JF - Revista Colombiana de Nefrología JA - Rev. Colomb. Nefrol. VL - 7 IS - Supl.2 SE - Review DO - 10.22265/acnef.7.Supl.2.407 UR - https://revistanefrologia.org/index.php/rcn/article/view/407 SP - AB - <p><strong>Introduction:</strong> Due to the emergence of the SARS-CoV-2 coronavirus since December 2019, a large volume of scientific production has been generated, in some cases uncertain or controversial, especially in the pharmacological management of patients with this infection; therefore, it is considered a relevant search for methodological alternatives to carry out its rigorous, systematic and quality synthesis, but with less execution time and lower cost.</p><p><strong>Objective:</strong> To present the available evidence regarding the pharmacological management of people with suspected or diagnosed respiratory SARS-CoV-2 (COVID-19) using the method of rapid systematic reviews (RS-R) in potentially effective drugs for their management.</p><p><strong>Methodology:</strong> A systematic and structured search was conducted in Medline, Embase, Scopus, Cochrane Library, Clinical trials and Google Scholar in English. Studies included clinical practice guidelines, consensus, systematic reviews, meta-analyses, clinical trials, and other primary studies. Data search and extraction were performed by multiple reviewers, but none were paired.</p><p><strong>Results:</strong> Sixteen questions of clinical interest were resolved, related to the use in COVID-19 of lopinavir/ritonavir, nelfinavir, oseltamivir, remdesivir, ribavirin, teicoplanin, umifenovir, favipiravir, tocilizumab, ivermectin, convalescent plasma; the use of support management drugs such as dexamethasone were also evaluated, as well as the concomitant use of drugs that generated doubts, such as NSAIDs, ACEis, and ARA IIs.</p><p><strong>Conclusions:</strong> Summaries of evidence are within the pandemic scenario as a good methodological alternative to offer quality information in the short term for decision-makers.</p> ER -